GLP1R and myocardial infarction: CVOTs evaluating GLP-1 receptor agonist’s (GLP-1 RA) effects on cardiovascular outcomes have consistently shown a reduction in MACE rates, primarily in rates of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death.